Zacks Company Profile for Evolus, Inc. (EOLS : NSDQ) |
|
|
|
Company Description |
Evolus, Inc. is a medical aesthetics company. It focuses on providing physicians and patients in aesthetic procedures and treatments. The company focuses on the self-pay aesthetic market and its lead product candidate, DWP-450, is an injectable 900 kDa purified botulinum toxin type A complex. Evolus, Inc. is based in Irvine, California.
Number of Employees: 332 |
|
|
|
Price / Volume Information |
Yesterday's Closing Price: $9.21 |
Daily Weekly Monthly
 |
20 Day Moving Average: 955,641 shares |
Shares Outstanding: 64.48 (millions) |
Market Capitalization: $593.82 (millions) |
Beta: 0.97 |
52 Week High: $17.82 |
52 Week Low: $8.67 |
Short Interest Ratio: |
|
% Price Change |
% Price Change Relative to S&P 500 |
4 Week |
-7.62% |
-11.63% |
12 Week |
-10.06% |
-26.62% |
Year To Date |
-16.58% |
-20.92% |
|
|
|
|
|
Address & Contact Information |
Street Address |
Phone / Fax |
Email Address |
Web URL |
520 Newport Center Dr. Suite 1200 - Newport Beach,CA 92660 USA |
ph: 949-284-4555 fax: - |
ir@evolus.com |
http://www.evolus.com |
|
|
|
General Corporate Information |
Officers
David Moatazedi - President and Chief Executive Officer
Vikram Malik - Chairman
Sandra Beaver - Chief Financial Officer
Simone Blank - Director
David Gill - Director
|
|
Peer Information
Evolus, Inc. (BJCT)
Evolus, Inc. (CADMQ)
Evolus, Inc. (APNO)
Evolus, Inc. (UPDC)
Evolus, Inc. (IMTIQ)
Evolus, Inc. (CYGN)
|
|
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED PRODUCTS
Sector: Medical
CUSIP: 30052C107
SIC: 2834
|
|
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 07/30/25
|
|
Share - Related Items
Shares Outstanding: 64.48
Most Recent Split Date: (:1)
Beta: 0.97
Market Capitalization: $593.82 (millions)
|
|
|
|
|
|
EPS Information |
Dividend Information |
Analyst Coverage: No |
Dividend Yield: 0.00% |
Current Fiscal Quarter EPS Consensus Estimate: $-0.18 |
Indicated Annual Dividend: $0.00 |
Current Fiscal Year EPS Consensus Estimate: $-0.47 |
Payout Ratio: |
Number of Estimates in the Fiscal Year Consensus: 2.00 |
Change In Payout Ratio: |
Estmated Long-Term EPS Growth Rate: % |
Last Dividend Paid: NA - $0.00 |
Next EPS Report Date: 07/30/25 |
|
|
|
|